Agenus regains compliance with nasdaq minimum bid price requirement

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in immunology-based therapies for cancer, received notice from nasdaq on april 30, 2024, that the company has regained compliance with the $1.00 minimum bid price requirement set forth in nasdaq listing rule 5550(a)(2). accordingly, the company now satisfies all requirements for continued listing on the nasdaq capital market and the matter is now closed. about agenus agenus is a leading immuno-oncology company ta.
AGEN Ratings Summary
AGEN Quant Ranking